重度卵巢过度刺激综合征女性的危及生命的并发症
该研究基于美国全国住院患者样本,纳入2002至2011年11562例重度卵巢过度刺激综合征住院患者,分析危及生命的并发症(深静脉血栓/肺栓塞、急性呼吸窘迫综合征、急性肾衰竭、插管)的相关因素。结果显示4.4%患者发生危及生命的并发症,年龄≥40岁、有合并症及非裔美国患者风险更高,并发症与更长住院时间和更高费用相关。
要点
- 重度卵巢过度刺激综合征住院患者中4.4%发生危及生命的并发症。
- 年龄≥40岁、有合并症及非裔美国患者发生危及生命的并发症风险更高。
- 发生危及生命的并发症与更长住院时间和更高住院费用相关。
核心结论
- 在重度卵巢过度刺激综合征背景下,具有常见医学合并症的患者发生危及生命的并发症风险更高。
- 这些并发症与高住院费用和医院负担相关。
- 鉴于接受体外受精且伴有医学合并症的患者数量不断增加,可能需要对高危患者进行更密切的监测。
- 随着辅助生殖技术实践的变化及旨在降低卵巢过度刺激综合征风险的策略的实施,未来需要研究评估这些变化对住院和并发症风险的影响。
研究设计与样本
- 研究纳入2002至2011年美国全国住院患者样本中重度卵巢过度刺激综合征的住院病例,共11562例患者。
- 采用调查校正的多变量逻辑回归分析,控制危险因素,以调整比值比(95%置信区间)为效应量。
主要发现
- 11562例患者中,白人占55.7%,有私人保险者占87.7%,年龄25-39岁者占84.6%,城市医院住院者占95%。
- 19.3%的患者有医学合并症,包括高血压、糖尿病、肥胖、甲状腺功能减退和贫血。
- 4.4%的患者发生危及生命的并发症(深静脉血栓/肺栓塞2.2%;急性肾衰竭;急性呼吸窘迫综合征0.9%;插管0.5%)。
- 年龄≥40岁(比值比4.02;95%置信区间1.37, 11.76)、有合并症(比值比2.29;95%置信区间1.46, 3.57)及非裔美国患者(比值比2.15;95%置信区间1.25, 3.70)更可能发生危及生命的状况。
- 有医学合并症的患者(比值比0.39;95%置信区间0.24, 0.63)常规出院的可能性更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian hyperstimulation syndrome is a potentially life-threatening clinical condition. OBJECTIVE: The objective of this study was to evaluate risk factors for life-threatening complications for patients with severe ovarian hyperstimulation syndrome in a United States nationwide sample. MATERIALS AND METHODS: Ovarian hyperstimulation syndrome admissions from 2002 to 2011 from the Nationwide Inpatient Sample were included in this study. The association between patient and hospital factors and life-threatening complications (deep vein thrombosis/pulmonary embolism, acute respiratory distress syndrome, acute renal failure, intubation), nonroutine discharge (discharge to skilled nursing facility, transfer hospital), prolonged length of stay, and total hospital charges were analyzed. Survey-adjusted multivariable logistic regression analyses were performed for these outcomes, controlling for risk factors, with adjusted odds ratios with 95% confidence intervals as the measures of effect. RESULTS: A total of 11,562 patients were hospitalized with severe ovarian hyperstimulation syndrome from 2002 to 2011. The majority were white (55.7%), with private insurance (87.7%), aged 25-39 years (84.6%), and hospitalized in an urban location (95%). In all, 19.3% of patients had medical comorbidities including hypertension, diabetes, obesity, hypothyroidism, and anemia. Life-threatening complications occurred in 4.4% of patients (deep vein thrombosis/pulmonary embolism, 2.2%; acute renal failure; acute respiratory distress syndrome, 0.9%; intubation, 0.5%). Patients ≥40 years old (odds ratio, 4.02; 95% confidence interval, 1.37, 11.76), those with comorbidities (odds ratio, 2.29; 95% confidence interval, 1.46, 3.57), and African American patients (odds ratio, 2.15; 95% confidence interval, 1.25, 3.70) were more likely to develop life-threatening conditions. Patients with medical comorbidities (odds ratio, 0.39; 95% confidence interval, 0.24, 0.63) were also less likely to be routinely discharged from the hospital. Adjusting for patient and hospital demographics, patients with comorbidities were more likely to develop deep vein thrombosis/pulmonary embolism (adjusted odds ratio, 2.44; 95% confidence interval, 1.28, 4.65) and acute renal failure (adjusted odds ratio, 2.26; 95% confidence interval, 1.21, 4.23). Patients who developed life-threatening complications had longer hospital length of stay (adjusted odds ratio, 3.72; 95% confidence interval, 2.28, 6.07) and higher hospital costs (adjusted odds ratio, 5.20; 95% confidence interval, 3.22,8.39). CONCLUSION: Patients with common medical comorbidities are at higher risk for life-threatening complications in the setting of severe ovarian hyperstimulation syndrome. Furthermore, these complications are associated with high hospital costs and hospital burden. Given the increasing number of in vitro fertilization patients with medical comorbidities, closer monitoring of at-risk patients may be indicated. As assisted reproductive technology practice changes in recent years with strategies designed to reduce ovarian hyperstimulation syndrome risk, future studies are needed to assess the impact of these changes on hospitalization and complication risk.
引用
- Selter J, Wen T, Palmerola KL, et al. Life-threatening complications among women with severe ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 2019. PMID: 30742828. doi:10.1016/j.ajog.2019.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。